| 000 | 01342 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250518053456.0 | ||
| 264 | 0 | _c20200528 | |
| 008 | 202005s 0 0 eng d | ||
| 022 | _a1468-1293 | ||
| 024 | 7 |
_a10.1111/hiv.12788 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrogan, A J | |
| 245 | 0 | 0 |
_aIs increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. _h[electronic resource] |
| 260 |
_bHIV medicine _c11 2019 |
||
| 300 |
_a668-680 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHIV Infections _xdiagnosis |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 |
_aMass Screening _xeconomics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPublic Health |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aUnited Kingdom |
| 700 | 1 | _aTalbird, S E | |
| 700 | 1 | _aDavis, A E | |
| 700 | 1 | _aWild, L | |
| 700 | 1 | _aFlanagan, D | |
| 773 | 0 |
_tHIV medicine _gvol. 20 _gno. 10 _gp. 668-680 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/hiv.12788 _zAvailable from publisher's website |
| 999 |
_c29986087 _d29986087 |
||